|
Drug
|
S. aureus
|
E. faecium*
|
E. faecalis*
|
|---|
| |
CA 13
|
HA 17
|
CA 12
|
HA 9
|
CA 9
|
HA 6
|
|---|
|
Penicillin
|
0
|
0
|
10
|
0
|
17
|
75
|
|
Ampicillin*
|
-
|
-
|
25
|
11
|
100
|
100
|
|
Amoxicillin-clavulanate
|
77
|
50
|
70
|
11†
|
100
|
100
|
|
Cloxacillin
|
92
|
88
|
-
|
-
|
-
|
-
|
|
Cefuroxime
|
92
|
88
|
-
|
-
|
-
|
-
|
|
Ceftazidime
|
85
|
80
|
-
|
-
|
-
|
-
|
|
Meropenem
|
100
|
100
|
-
|
-
|
-
|
-
|
|
Gentamicin*
|
100
|
81
|
67
|
33
|
56
|
67
|
|
Vancomycin*
|
100
|
100
|
100
|
100
|
100
|
100
|
|
Erythromycin
|
100
|
71
|
0
|
0
|
22
|
33
|
|
Doxycycline
|
62
|
35
|
9
|
0
|
25
|
0
|
|
Co-trimoxazole
|
69
|
63
|
27
|
0
|
67
|
40
|
|
Chloramphenicol
|
85
|
73
|
50
|
11
|
38
|
33
|
|
Ciprofloxacin*
|
77
|
81
|
42
|
22
|
100
|
100
|
|
Linezolid*
|
-
|
-
|
100
|
100
|
100
|
100
|
|
Quinupristin-dalfopristin*
|
-
|
-
|
100
|
100
|
0
|
17
|
- CA, community-acquired infection; HA, hospital-acquired infection; "-", not done. *E-test was used for susceptibility testing of enterococci against ampicillin, ciprofloxacillin, linezolid, quinupristin-dalfopristin, vancomycin and high-level gentamicin resistance. † Statistically significant difference in susceptibility among hospital-acquired and community-acquired isolates, p < 0.05 by two-sided Fisher's exact test.
